|

A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）

RECRUITINGSponsored by Drug Induced Liver Disease Study Group
Actively Recruiting
SponsorDrug Induced Liver Disease Study Group
Started2016-04
Est. completion2030-12
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT02961413

Summary

This is a multi-center, prospective, non-interventional cohort study . Its primary objectives are: 1. assess DILI patients' clinical characteristics, disease progression and influencing factors in clinical practice; 2. learn about suspected drug caused DILI,rechallenging, liver biochemical abnormalities mode, etc.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Diagnosis of DILI patients with various types and severity according to the 2015 version of the Chinese DILI treatment guidelines
* RUCAM ≥6, or RUCAM between 3-5 is required by the three experts determined that the drug-induced liver injury
* patient can provide informed consent form

Exclusion Criteria:

* non-drug-induced liver injury

Conditions2

Drug Induced Liver InjuryLiver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.